<i>N</i> 1,<i>N</i>12-Diacetylspermine as a Sensitive and Specific Novel Marker for Early- and Late-Stage Colorectal and Breast Cancers

• Kyoko Hiramatsu

  1Medical Research and Development Center, Tokyo Metropolitan Institute of Medical Science,

• Keiichi Takahashi

  2Department of Surgery,

• Taturo Yamaguchi

  2Department of Surgery,

• Hiroshi Matsumoto

  2Department of Surgery,

• Hidenori Miyamoto

  2Department of Surgery,

• Souichi Tanaka

  5Department of Surgery, Tokyo Metropolitan Bokutou Hospital, and

• Chikako Tanaka

  2Department of Surgery,

• Yoshiko Tamamori

  3Clinical Laboratory,

• Mari Imajo

  6Department of Applied Chemistry, Kogakuin University

• Masashi Kawaguchi

  6Department of Applied Chemistry, Kogakuin University

• Masakazu Toi

  2Department of Surgery,

• Takeo Mori

  4Tokyo Metropolitan Komagome Hospital,

• Masao Kawakita

  6Department of Applied Chemistry, Kogakuin University

抄録

Purpose: N 1,N12-diacetylspermine (DiAcSpm) in the urine of colorectal and breast cancer patients was examined to establish its usefulness as a novel diagnostic tool for detecting these cancers at clinically early stages. Experimental Design: Urine samples from 248 colon cancer patients and 83 breast cancer patients as well as 51 patients with benign gastrointestinal diseases treated in Tokyo Metropolitan Komagome Hospital during the period of August 1999 to January 2004 were collected. DiAcSpm was analyzed by ELISA and its sensitivity for malignant conditions was compared with that of serum carcinoembryonic antigen (CEA), CA19-9, and CA15-3. Results: The sensitivity of urinary DiAcSpm for colon cancer patients (n = 248) was 75.8% (mean ± 2 SD for 52 healthy controls as a cutoff value), which was markedly higher than the sensitivities of serum CEA (39.5%, P &lt; 0.0001) and CA19-9 (14.1%, P &lt; 0.0001). DiAcSpm was elevated in 60% of tumor-node-metastasis cancer stage 0 + I patients, whereas only 10% (P &lt; 0.0001) and 5% (P &lt; 0.0001) of these patients were CEA- and CA19-9–positive, respectively. The sensitivity of urinary DiAcSpm for 83 cases of breast cancer (60.2%) was higher than the sensitivities of CEA (37.3%, P = 0.0032) and CA15-3 (37.3%, P = 0.0032). DiAcSpm was elevated in 28% of tumor-node-metastasis stage I + II patients, whereas only 3% (P = 0.0064) and 0% (P = 0.001) of these patients were CEA- and CA15-3–positive, respectively. Conclusion: The observations indicate that urinary DiAcSpm is a more sensitive marker than CEA, CA19-9, and CA15-3 and that it can efficiently detect colorectal and breast cancers at early stages.

収録刊行物

• Clinical Cancer Research

  Clinical Cancer Research 11 (8), 2986-2990, 2005-04-15

  American Association for Cancer Research (AACR)

キーワード

• Cancer Research
• Oncology

詳細情報

• CRID: 1360574094769673472
• NII論文ID: 30018690978
• DOI: 10.1158/1078-0432.ccr-04-2275
• ISSN: 15573265
• ISSN: 10780432
• ISSN: http://id.crossref.org/issn/10780432
• Web Site: https://aacrjournals.org/clincancerres/article-pdf/11/8/2986/1961556/2986-2990.pdf
• データソース種別:
  • Crossref
  • CiNii Articles
  • KAKEN